169 related articles for article (PubMed ID: 10708452)
1. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions.
Chirmule N; Raper SE; Burkly L; Thomas D; Tazelaar J; Hughes JV; Wilson JM
J Virol; 2000 Apr; 74(7):3345-52. PubMed ID: 10708452
[TBL] [Abstract][Full Text] [Related]
2. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues.
Yang Y; Su Q; Grewal IS; Schilz R; Flavell RA; Wilson JM
J Virol; 1996 Sep; 70(9):6370-7. PubMed ID: 8709265
[TBL] [Abstract][Full Text] [Related]
3. Th2-dependent B cell responses in the absence of CD40-CD40 ligand interactions.
Chirmule N; Tazelaar J; Wilson JM
J Immunol; 2000 Jan; 164(1):248-55. PubMed ID: 10605018
[TBL] [Abstract][Full Text] [Related]
4. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.
Kay MA; Meuse L; Gown AM; Linsley P; Hollenbaugh D; Aruffo A; Ochs HD; Wilson CB
Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4686-91. PubMed ID: 9114052
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates.
Elster EA; Xu H; Tadaki DK; Montgomery S; Burkly LC; Berning JD; Baumgartner RE; Cruzata F; Marx R; Harlan DM; Kirk AD
Transplantation; 2001 Nov; 72(9):1473-8. PubMed ID: 11707732
[TBL] [Abstract][Full Text] [Related]
6. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway.
Scaria A; St George JA; Gregory RJ; Noelle RJ; Wadsworth SC; Smith AE; Kaplan JM
Gene Ther; 1997 Jun; 4(6):611-7. PubMed ID: 9231078
[TBL] [Abstract][Full Text] [Related]
7. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
[TBL] [Abstract][Full Text] [Related]
8. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector.
Ziller C; Stoeckel F; Boon L; Haegel-Kronenberger H
Gene Ther; 2002 May; 9(9):537-46. PubMed ID: 11973629
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis.
Blair PJ; Riley JL; Harlan DM; Abe R; Tadaki DK; Hoffmann SC; White L; Francomano T; Perfetto SJ; Kirk AD; June CH
J Exp Med; 2000 Feb; 191(4):651-60. PubMed ID: 10684857
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.
Haegel-Kronenberger H; Haanstra K; Ziller-Remy C; Ortiz Buijsse AP; Vermeiren J; Stoeckel F; Van Gool SW; Ceuppens JL; Mehtali M; De Boer M; Jonker M; Boon L
Gene Ther; 2004 Feb; 11(3):241-52. PubMed ID: 14737083
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral vector expressing ICP47 inhibits adenovirus-specific cytotoxic T lymphocytes in nonhuman primates.
Scaria A; Sullivan JA; St George JA; Kaplan JM; Lukason MJ; Morris JE; Plog M; Nicolette C; Gregory RJ; Wadsworth SC
Mol Ther; 2000 Nov; 2(5):505-14. PubMed ID: 11082324
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates.
Shean MK; Baskin G; Sullivan D; Schurr J; Cavender DE; Shellito JE; Schwarzenberger PO; Kolls JK
Hum Gene Ther; 2000 May; 11(7):1047-55. PubMed ID: 10811233
[TBL] [Abstract][Full Text] [Related]
13. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates.
Xu H; Tadaki DK; Elster EA; Burkly LC; Berning JD; Cruzata F; Kampen RL; Montgomery SP; Patterson NB; Harlan DM; Kirk AD
Transplantation; 2002 Oct; 74(7):940-3. PubMed ID: 12394834
[TBL] [Abstract][Full Text] [Related]
14. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.
Oxenius A; Campbell KA; Maliszewski CR; Kishimoto T; Kikutani H; Hengartner H; Zinkernagel RM; Bachmann MF
J Exp Med; 1996 May; 183(5):2209-18. PubMed ID: 8642330
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2.
Kaplan JM; St George JA; Pennington SE; Keyes LD; Johnson RP; Wadsworth SC; Smith AE
Gene Ther; 1996 Feb; 3(2):117-27. PubMed ID: 8867859
[TBL] [Abstract][Full Text] [Related]
16. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.
Van den Eertwegh AJ; Noelle RJ; Roy M; Shepherd DM; Aruffo A; Ledbetter JA; Boersma WJ; Claassen E
J Exp Med; 1993 Nov; 178(5):1555-65. PubMed ID: 7693849
[TBL] [Abstract][Full Text] [Related]
17. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody.
Chirmule N; Truneh A; Haecker SE; Tazelaar J; Gao Gp; Raper SE; Hughes JV; Wilson JM
J Immunol; 1999 Jul; 163(1):448-55. PubMed ID: 10384148
[TBL] [Abstract][Full Text] [Related]
18. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.
Foy TM; Shepherd DM; Durie FH; Aruffo A; Ledbetter JA; Noelle RJ
J Exp Med; 1993 Nov; 178(5):1567-75. PubMed ID: 7693850
[TBL] [Abstract][Full Text] [Related]
19. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration.
Wilson CB; Embree LJ; Schowalter D; Albert R; Aruffo A; Hollenbaugh D; Linsley P; Kay MA
J Virol; 1998 Sep; 72(9):7542-50. PubMed ID: 9696851
[TBL] [Abstract][Full Text] [Related]
20. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.
Thacker EE; Nakayama M; Smith BF; Bird RC; Muminova Z; Strong TV; Timares L; Korokhov N; O'Neill AM; de Gruijl TD; Glasgow JN; Tani K; Curiel DT
Vaccine; 2009 Nov; 27(50):7116-24. PubMed ID: 19786146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
